Background: To meet clinical needs, fluorescence-guided surgery has emerged as a new technique that guides surgeons in the resection of cancerous tissue by highlighting tumour lesions during surgery. We aimed to evaluate the novel ovarian cancer-specific antibody fluorescent probe COC183B2-800 (COC183B2 conjugated with IRDye800CW) in tumour-specific imaging to determine if it can help surgeons remove malignant lesions under fluorescence guidance.
Methods: The expression of OC183B2 antigen in epithelial ovarian cancer (EOC) tissues and cell lines was determined using immunohistochemistry (IHC). Western blotting was used to verify the expression of OC183B2 in SKOV3-Luc tumours. Antibodies against OC183B2 and mouse immunoglobulin G1 (IgG1) were conjugated with IRDye800CW to develop the antibody fluorescent probes COC183B2-800 and IgG-800 (immunoglobulin G1 conjugated with IRDye800CW). A subcutaneous mouse tumour model of SKOV3-Luc cells was constructed. Bioluminescent imaging (BLI) was conducted to detect the tumour location. Near-infrared fluorescence (NIRF) imaging was performed after the mice were injected with imaging agents. The mice were sacrificed 96 h postinjection, and the biodistribution assays were performed using NIRF imaging.
Results: In 69 EOC patients, the total positive rate of OC183B2 in EOC tissues was 89.9% (62/69). Expression of the OC183B2 antigen was positive in SKOV3-Luc, 3AO, ES2 and A2780 cells. The OC183B2 antigen could be detected in SKOV3-Luc tumours. NIRF imaging of the COC183B2-800 probe at different doses showed a high fluorescent signal at the tumour location that was in line with the site detected by bioluminescent imaging. The tumour background ratio (TBR) was significantly higher in the COC183B2-800 group than in the IgG-800, IRDye800CW and PBS groups. The fluorescent probe COC183B2-800 is metabolized mainly through the liver and does not accumulate in other organs.
Conclusions: COC183B2-800 shows effective tumour-specific targeting of EOC and is a promising diagnostic and therapeutic tool for fluorescence-guided surgery.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137188 | PMC |
| http://dx.doi.org/10.1186/s12957-020-01843-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preoperative PET imaging and fluorescence-guided surgery of human glioblastoma using dual-labeled antibody targeting ET receptors in a preclinical mouse model: A theranostic approach.
Theranostics
October 2024
Université de Bourgogne, ICMUB UMR CNRS 6302, Dijon, 21000, France.
Glioblastoma (GBM) poses significant challenges regarding complete tumor removal due to its heterogeneity and invasiveness, emphasizing the need for effective therapeutic options. In the last two decades, fluorescence-guided surgery (FGS), employing fluorophores such as 5-aminolevulinic acid (5-ALA) to enhance tumor delineation, has gained attraction among neurosurgeons. However, some low-grade tumors do not show any accumulation of the tracers, and the lack of patient stratification represents an important limitation.
View Article and Find Full Text PDFTargeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody.
Ann Surg Oncol
September 2024
Department of Surgery, University of California San Diego, La Jolla, CA, USA.
Background: Gastric cancer poses a major diagnostic and therapeutic challenge as surgical resection provides the only opportunity for a cure. Specific labeling of gastric cancer could distinguish resectable and nonresectable disease and facilitate an R0 resection, which could improve survival.
Methods: Two patient-derived gastric cancer lines, KG8 and KG10, were established from surgical specimens of two patients who underwent gastrectomy for gastric adenocarcinoma.
Hepatic Biotransformation of Renal Clearable Gold Nanoparticles for Noninvasive Detection of Liver Glutathione Level via Urinalysis.
Angew Chem Int Ed Engl
September 2024
Center for Medical Research on Innovation and Translation, Institute of Clinical Medicine, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, P.R. China.
Article Synopsis
- Renal clearable nanoparticles can effectively eliminate from the body through the kidneys, preventing harmful accumulation, but their interactions with other organs like the liver are still not fully understood.
- This study focused on a specific type of nanoparticle (800CW-GS-Au) that, despite showing minimal liver accumulation, underwent modifications due to liver interactions, which could be detected in urine.
- The findings suggest a way to noninvasively measure liver glutathione levels through urine analysis, enhancing understanding of nanoparticle transport and paving the way for new diagnostic methods.
Increasing the Dye Payload of Cetuximab-IRDye800CW Enables Photodynamic Therapy.
Mol Pharm
July 2024
Department of Bioengineering, University of Texas at Dallas, Richardson 75080-3021, Texas, United States.
Article Synopsis
- Cetuximab (Cet)-IRDye800CW is an antibody-IRDye800CW conjugate that shows promise for identifying tumor margins during fluorescence-guided surgery and is being explored for post-surgery treatment of residual cancer cells using photodynamic therapy (PDT).
- The study highlights that increasing the number of dye molecules attached to the antibody from 2 to 11 enhances the effectiveness of Cet-IRDye800CW, enabling it to produce reactive species that can harm cancer cells, inducing approximately 90% phototoxicity in FaDu head and neck cancer cells.
- Antibody-targeted PDT with the higher dye payload offers improved cancer cell specificity and reduced toxicity in non-cancerous
Intraoperative Resection Guidance and Rapid Pathological Diagnosis of Osteosarcoma using B7H3 Targeted Probe under NIR-II Fluorescence Imaging.
Adv Sci (Weinh)
September 2024
Department of Musculoskeletal Tumor & Beijing Key Laboratory of Musculoskeletal Tumor, Peking University People's Hospital, Beijing, 100044, China.
Complete removal of all tumor tissue with a wide surgical margin is essential for the treatment of osteosarcoma (OS). However, it's difficult, sometimes impossible, to achieve due to the invisible small satellite lesions and blurry tumor boundaries. Besides, intraoperative frozen-section analysis of resection margins of OS is often restricted by the hard tissues around OS, which makes it impossible to know whether a negative margin is achieved.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!